CUSTOMER PORTAL

 

Welcome to the Sysmex Customer Portal.

If you have a login for the site, please sign in using the form below. If you have forgotten your details please click here  

This page requires that you know the email address that you've been signed up with. If you wish to log a support call please using the link on the right below and then sign in with your site's username and password. If you are unsure about any of this information please contact the Training Academy on 0870 0666960

http://academy.sysmex.co.uk/

Earlier recognition. Better survival rates. Synergy in expertise.

Over 400,000 of new cases of colorectal cancer are diagnosed in Europe each year. Yet early recognition, individualising cancer therapy, and using less invasive diagnostics are leading to improved prognoses and greater quality of life. Identifying the cancer early on is especially important for therapeutic success. Screening – both symptomatic and especially large-scale – is essential.

Explore our Colorectal Cancer solutions.

Screening

The quantitative FOB Gold FIT (Faecal immunological testing) screening test delivers more reliable results than the standard qualitative test. Extremely flexible, it can be adapted to screening programmes of any size and to laboratories with all throughputs.

Diagnostics

When determining therapy, often whether to give chemotherapy or not, the stage of the cancer is decisive. Sensitive, standardised lymph node diagnostics and the resulting nodal status are essential here. OSNA delivers the sensitivity and standardisation required and reduces false-negatives compared to classic histopathology.

Therapy

Using antibodies alongside chemotherapy has improved the overall survival of CRC patients.1 But clinicians must test stringently which patients are eligible. The OncoBEAMTM RAS CRC test uses a blood sample instead of tumour tissue and overcomes the limitations of tissue biopsies like sample availability, turnaround time and tumour heterogeneity.

Literature

  1. Lee J.J. et al. (2016): Options for Second-Line Treatment in Metastatic Colorectal Cancer. Clinical Advances in Hematology & Oncology, 14(1):46-54.

Oncology

Oncology Report - New Customer Magazine

Watch the video
A patient report
Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
Sysmex Urinalysis
See the features